The Allergy Diagnostics and Therapeutics Market is thriving due to rising allergy prevalence and advancements in immunotherapy and diagnostics. Market growth is accelerated by technological ...

US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults ...

Lower doses of peanut might help children with their peanut allergies Children had about the same amount of benefit from low and high doses of peanut Kids on the lower dose also had fewer side effects ...

Allergies are becoming more prevalent in the US, affecting over 100 million individuals. Common allergies include eczema, seasonal, and food allergies. Not surprisingly, food allergies can be the most ...

Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and ...

Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection to peanut, finds a new study led by The Hospital for Sick Children (SickKids) and ...

Feeding babies foods containing peanut as early as possible can help prevent peanut allergy. But many parents remain confused about this tactic and require more support to get it right, researchers ...

Confusion about introducing peanut to a baby’s diet early can keep parents from taking steps to ward off peanut allergy Some parents mistakenly believe it’s meant to test if their baby is allergic ...

Feeding babies peanut-containing foods as early as possible can help prevent peanut allergy, but a new study published in JAMA Network Open found that parents need more support to get it right.

DBV Technologies (DBVT) climbed ~41% in the premarket on Wednesday after the French biotech announced that a Phase 3 trial for its Viaskin Peanut patch for children with peanut allergies reached its ...

Welcome to the DBV Technologies Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Jonathan Neely. Please go ...